Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Compare the effect of milrinone versus sildenafil in treatment of neonates with persistent pulmonary hypertension.
40 neonates with PPHN, met inclusion criteria, randomly assigned to 2 groups, each includes 20, first group received intravenous milrinone and second group received nasogastric sildenafil. both groups receive other supportive care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| milrinone | Active Comparator | Milrinone is a phosphodiesterase inhibitor typ3 used in treatment of PPHN. used in dose (0.25 to 0.75 mg/kg/min) intravenous infusion compared with nasogastric sildenafil. |
|
| sildenafil | Active Comparator | Sildenafil is a phosphodiesterase inhibitor typ 5 used in treatment of PPHN. used in dose (0.2 to 0.5 mg/kg/6h) by nasogastric tube compared with intravenous milrinone infusion. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Milrinone | Drug | milrinone lactate, 1mg/ml, for intra venous use only |
|
| Measure | Description | Time Frame |
|---|---|---|
| efficacy of milrinone versus sildenafil in treatment of PPHN | effect on oxygenation index | 6 - 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| final outcome | Mortality | 6 - 12 months |
| Bleeding | Bleeding (e.g pulmonary hemorrhage) that is believed to be attributed to medication |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35881893 | Derived | Imam SS, El-Farrash RA, Taha AS, Saleh GA. Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial. J Cardiovasc Pharmacol. 2022 Nov 1;80(5):746-752. doi: 10.1097/FJC.0000000000001332. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020105 | Milrinone |
| D000068677 | Sildenafil Citrate |
| ID | Term |
|---|---|
| D000676 | Amrinone |
| D000631 | Aminopyridines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D011725 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sildenafil | Drug | 50mg sildenafil citrate/tablet, crushed in water taken by nasogastric tube |
|
|
| 6-12 months |
| Ventilation | total duration of mechanical ventilation | 6-12 months |
| Ventilatory settings | highest ventilator settings | 6-12 months |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D010879 | Piperazines |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |